Atossa Therapeutics, Inc. said CVR holders are entitled to 25% of net proceeds from monetizing its first priority review voucher, capped at $50 million. Third-quarter operating expenses were $5.9 million, down from $9.3 million.
ATOS · Atossa Therapeutics, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Atossa Therapeutics said (Z)-endoxifen is being investigated in four Phase 2 trials. Nine-month 2026 operating expenses were $24.5 million, down from $25.7 million, and net cash used in operating activities was (24,745) thousand.
Atossa Therapeutics declared one stapled contingent value right per common share, payable from 25% of net proceeds of the first FDA priority review voucher awarded by December 31, 2036, up to $50 million. No voucher has been awarded.
Atossa Therapeutics approved a plan to issue one contingent value right per common share, entitling holders to 25% of net proceeds from monetizing its first qualifying rare pediatric disease priority review voucher, subject to a $50 million aggregate payment cap.